810 related articles for article (PubMed ID: 21844879)
1. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
[TBL] [Abstract][Full Text] [Related]
3. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
4. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
[TBL] [Abstract][Full Text] [Related]
5. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
[TBL] [Abstract][Full Text] [Related]
8. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X; Astrup A; Fujioka K; Greenway F; Halpern A; Krempf M; Lau DC; le Roux CW; Violante Ortiz R; Jensen CB; Wilding JP;
N Engl J Med; 2015 Jul; 373(1):11-22. PubMed ID: 26132939
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
[TBL] [Abstract][Full Text] [Related]
13. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
14. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
[TBL] [Abstract][Full Text] [Related]
15. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
van Can J; Sloth B; Jensen CB; Flint A; Blaak EE; Saris WH
Int J Obes (Lond); 2014 Jun; 38(6):784-93. PubMed ID: 23999198
[TBL] [Abstract][Full Text] [Related]
16. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.
Ariel D; Kim SH; Abbasi F; Lamendola CA; Liu A; Reaven GM
Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1317-22. PubMed ID: 25280957
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
[TBL] [Abstract][Full Text] [Related]
18. Zonisamide for weight loss in obese adults: a randomized controlled trial.
Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
[TBL] [Abstract][Full Text] [Related]
19. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
[TBL] [Abstract][Full Text] [Related]
20. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
Blackman A; Foster GD; Zammit G; Rosenberg R; Aronne L; Wadden T; Claudius B; Jensen CB; Mignot E
Int J Obes (Lond); 2016 Aug; 40(8):1310-9. PubMed ID: 27005405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]